|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GOLT1A |
Gene summary for GOLT1A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GOLT1A | Gene ID | 127845 |
| Gene name | golgi transport 1A | |
| Gene Alias | CGI-141 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6ZVE7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 127845 | GOLT1A | NAFLD1 | Human | Liver | NAFLD | 3.03e-02 | 3.47e-01 | -0.04 |
| 127845 | GOLT1A | S43 | Human | Liver | Cirrhotic | 2.21e-05 | -5.94e-02 | -0.0187 |
| 127845 | GOLT1A | HCC1_Meng | Human | Liver | HCC | 1.29e-69 | 3.25e-01 | 0.0246 |
| 127845 | GOLT1A | HCC2_Meng | Human | Liver | HCC | 2.37e-02 | -1.66e-01 | 0.0107 |
| 127845 | GOLT1A | HCC2 | Human | Liver | HCC | 5.11e-04 | 3.03e+00 | 0.5341 |
| 127845 | GOLT1A | Pt14.a | Human | Liver | HCC | 2.53e-02 | 2.25e-01 | 0.0169 |
| 127845 | GOLT1A | S014 | Human | Liver | HCC | 2.90e-29 | 1.58e+00 | 0.2254 |
| 127845 | GOLT1A | S015 | Human | Liver | HCC | 3.63e-30 | 1.93e+00 | 0.2375 |
| 127845 | GOLT1A | S016 | Human | Liver | HCC | 1.54e-33 | 1.74e+00 | 0.2243 |
| 127845 | GOLT1A | S027 | Human | Liver | HCC | 6.22e-17 | 1.53e+00 | 0.2446 |
| 127845 | GOLT1A | S028 | Human | Liver | HCC | 3.92e-29 | 1.62e+00 | 0.2503 |
| 127845 | GOLT1A | S029 | Human | Liver | HCC | 4.76e-36 | 2.42e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00481936 | Liver | NAFLD | Golgi vesicle transport | 66/1882 | 296/18723 | 3.66e-10 | 9.30e-08 | 66 |
| GO:00068885 | Liver | NAFLD | endoplasmic reticulum to Golgi vesicle-mediated transport | 26/1882 | 130/18723 | 4.78e-04 | 6.78e-03 | 26 |
| GO:004819311 | Liver | Cirrhotic | Golgi vesicle transport | 153/4634 | 296/18723 | 1.02e-23 | 6.43e-21 | 153 |
| GO:000688811 | Liver | Cirrhotic | endoplasmic reticulum to Golgi vesicle-mediated transport | 77/4634 | 130/18723 | 5.78e-17 | 7.56e-15 | 77 |
| GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
| GO:000688821 | Liver | HCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 100/7958 | 130/18723 | 1.15e-15 | 8.67e-14 | 100 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GOLT1A | SNV | Missense_Mutation | rs868308808 | c.359N>T | p.Ala120Val | p.A120V | Q6ZVE7 | protein_coding | tolerated(0.28) | benign(0.006) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GOLT1A | SNV | Missense_Mutation | novel | c.376N>G | p.Gln126Glu | p.Q126E | Q6ZVE7 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| GOLT1A | SNV | Missense_Mutation | novel | c.284T>C | p.Phe95Ser | p.F95S | Q6ZVE7 | protein_coding | deleterious(0) | benign(0.371) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GOLT1A | SNV | Missense_Mutation | novel | c.200N>A | p.Gly67Glu | p.G67E | Q6ZVE7 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GOLT1A | SNV | Missense_Mutation | c.278N>A | p.Gly93Glu | p.G93E | Q6ZVE7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
| GOLT1A | SNV | Missense_Mutation | novel | c.235C>A | p.Leu79Ile | p.L79I | Q6ZVE7 | protein_coding | tolerated(0.11) | benign(0.437) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| GOLT1A | SNV | Missense_Mutation | novel | c.188A>G | p.His63Arg | p.H63R | Q6ZVE7 | protein_coding | deleterious(0.05) | benign(0.142) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GOLT1A | SNV | Missense_Mutation | rs187437980 | c.367N>T | p.Arg123Trp | p.R123W | Q6ZVE7 | protein_coding | deleterious(0) | possibly_damaging(0.773) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GOLT1A | SNV | Missense_Mutation | rs748780832 | c.277N>A | p.Gly93Arg | p.G93R | Q6ZVE7 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GOLT1A | SNV | Missense_Mutation | novel | c.139T>C | p.Ser47Pro | p.S47P | Q6ZVE7 | protein_coding | tolerated(0.19) | benign(0.02) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |